RAPP — Rapport Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. RESEARCH ROUNDUP- IQVIA Holdings, Reliance, United Therapeutics
Rapport Therapeutics ticks up after commencing $250 mln equity offering
Brief: Rapport Announces Proposed Public Offering Of Common Stock
Brief: Rapport Therapeutics Terminates ATM Prospectus - SEC Filing
U.S. STOCKS ON THE MOVE-Sanofi SA, Nutanix, Bullish
Rapport Therapeutics surges after seizure drug meets mid-stage trial goals
U.S. STOCKS ON THE MOVE-New Fortress Energy, Pulse Biosciences, US telecom stocks
U.S. STOCKS ON THE MOVE-Veeva, Gold miners, Ideaya Biosciences
Brief: Rapport Reports Positive Focal Onset Seizures Trial Results
Rapport Therapeutics surges after seizure drug meets main goals in mid-stage trial
Brief: Rapport Therapeutics To Announce Topline Results For Rap-219 Phase 2A Trial In Focal Onset Seizures On Monday, September 8, 2025
Rapport Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Rapport Therapeutics Reports Second Quarter 2025 Financials And Provides Business Update
Rapport Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Brief: Rapport Therapeutics Inc Q4 Net Loss $20.0 Million
Brief: Rapport Therapeutics Reports Q3 Financials And Provides Business Update
Brief: Johnson & Johnson Reports 6.8% Passive Stake In Rapport Therapeutics Inc As Of Sept 30- SEC Filing
U.S. RESEARCH ROUNDUP-Atlassian, Crowdstrike Holdings, CS Disco
Brief: James I. Healy Reports 5.5% Stake In Rapport Therapeutics Inc As Of June 10, 2024- SEC Filing